Cipargamin

Small molecule

Also known as KAE609

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (9)
Malaria
NCT07811908 · Novartis Pharmaceuticals
2026-02-12 – 2027-02-18 · Uncomplicated Plasmodium Falciparum Malaria
What this study did
NCT07811882 · Novartis Pharmaceuticals
2025-10-10 – 2026-07-01 · Uncomplicated Plasmodium Falciparum Malaria
What this study did
NCT05750628 · Novartis Pharmaceuticals
2024-01-23 – 2026-06-23 · Uncomplicated Plasmodium Falciparum Malaria
What this study did
NCT04675931 · Novartis Pharmaceuticals
2022-03-07 – 2025-08-20 · Severe Malaria
What this study did
NCT07235033 · Novartis Pharmaceuticals
2024-01-23 – 2025-03-19 · Uncomplicated Plasmodium Falciparum Malaria
What this study did
NCT03334747 · Novartis Pharmaceuticals
2017-11-16 – 2019-11-23 · Malaria
What this study did
NCT01836458 · Novartis Pharmaceuticals
2014-01 – 2015-03 · Malaria
What this study did
NCT01860989 · Novartis Pharmaceuticals
2013-07 – 2014-08 · Cure Rate
What this study did
Phase 1 (2)
Malaria
NCT04321252 · Novartis Pharmaceuticals
2020-07-22 – 2020-11-10 · Malaria
What this study did
NCT02543086 · Novartis Pharmaceuticals
2015-07 – 2015-09 · Plasmodium Falciparum Malaria
What this study did

Competitive landscape

This drug's own stage for Malaria: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cipargamin: this drugPhase 2Small moleculePfATP4not yet gradedNo reviewed efficacy summary in this indication
Ganaplacide / LumefantrinePhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
GSK3772701Phase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
GSK4024484Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
INE963
Phase 1(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
GSK4425689
—(overall)
UndisclosedCircumsporozoite protein (CSP)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cipargamin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
February 2027 (1)
Phase 2MalariaRecruiting
Est. primary completion 2027-02-04 · NCT07811908 · CT.gov ↗
What to watch

See the full readout calendar ↗